tiprankstipranks
Trending News
More News >
PT Kalbe Farma Tbk (PTKFF)
:PTKFF
US Market
Advertisement

PT Kalbe Farma Tbk (PTKFF) Price & Analysis

Compare
6 Followers

PTKFF Stock Chart & Stats


Financials

Options Prices

Currently, No data available
---

Ownership Overview

0.01%99.99%
Insiders
0.01% Other Institutional Investors
99.99% Public Companies and
Individual Investors

PTKFF FAQ

What was PT Kalbe Farma Tbk’s price range in the past 12 months?
PT Kalbe Farma Tbk lowest stock price was $0.06 and its highest was $0.14 in the past 12 months.
    What is PT Kalbe Farma Tbk’s market cap?
    PT Kalbe Farma Tbk’s market cap is $4.32B.
      When is PT Kalbe Farma Tbk’s upcoming earnings report date?
      PT Kalbe Farma Tbk’s upcoming earnings report date is Jul 31, 2025 which is in 5 days.
        How were PT Kalbe Farma Tbk’s earnings last quarter?
        Currently, no data Available
        Is PT Kalbe Farma Tbk overvalued?
        According to Wall Street analysts PT Kalbe Farma Tbk’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does PT Kalbe Farma Tbk pay dividends?
          PT Kalbe Farma Tbk pays a Annually dividend of $0.002 which represents an annual dividend yield of 31.74%. See more information on PT Kalbe Farma Tbk dividends here
            What is PT Kalbe Farma Tbk’s EPS estimate?
            PT Kalbe Farma Tbk’s EPS estimate for its next earnings report is not yet available.
            How many shares outstanding does PT Kalbe Farma Tbk have?
            PT Kalbe Farma Tbk has 46,813,390,000 shares outstanding.
              What happened to PT Kalbe Farma Tbk’s price movement after its last earnings report?
              Currently, no data Available
              Which hedge fund is a major shareholder of PT Kalbe Farma Tbk?
              Currently, no hedge funds are holding shares in PTKFF

              Company Description

              PT Kalbe Farma Tbk

              PT Kalbe Farma Tbk., together with its subsidiaries, develops, manufactures, and trades in pharmaceutical products in Indonesia. The company operates through four divisions: Prescription Pharmaceuticals, Consumer Health, Nutritionals, and Distribution and Logistic. It offers generic, branded, and licensed drugs, including Brainact, Cefspan, Mycoral, Cernevit, Cravit, Neuralgin, Broadced, Neurotam, Hemapo, and CPG that are distributed to hospitals, pharmacies, and drug stores. The company also provides over-the-counter drugs; energy drinks, ready-to-drink products, supplements, and other preventive products; and nutritional products for infants, toddlers, children, teenagers, adults, pregnant and lactating women, and elders, as well as for consumers with special medical needs. In addition, it offers contract services, including clinical study management, bioavailability/bioequivalence studies, and contract analysis to pharmaceutical companies; and animal health products, as well as operates Mitrasana Clinics, a health care service. Further, the company provides health screening services; operates as an agent and representative for biotechnology products; distributes consumer products, medical equipment, cosmetics, and other trading products; and trades in medical and laboratory equipment and supplies, raw materials for pharmaceutical products, and consumable products for hemodialysis therapy, as well as offers advertising services. PT Kalbe Farma Tbk. was incorporated in 1966 and is headquartered in Jakarta, Indonesia.
              Similar Stocks
              Company
              Price & Change
              Follow
              Dr Reddy's Laboratories
              Teva Pharmaceutical
              GlaxoSmithKline
              Sanofi
              Novartis
              Pfizer
              Popular Stocks
              What am I Missing?
              Make informed decisions based on Top Analysts' activity
              Know what industry insiders are buying
              Get actionable alerts from top Wall Street Analysts
              Find out before anyone else which stock is going to shoot up
              Get powerful stock screeners & detailed portfolio analysis